We use essential cookies and third-party cookies for content.

Arizona Tribune - Aytu BioPharma to Present at Upcoming September 2025 Conferences

Arizona Tribune
×
NYSE - LSE
CMSC -0.09% 21.29 $
JRI -0.4% 12.35 $
CMSD 0% 21.18 $
RBGPF 0.11% 70.77 $
RIO -1.43% 103.3 $
BP -0.45% 42.15 $
BCC -0.03% 78.75 $
AZN -1.12% 162.7 $
VOD 1% 16.04 $
BTI -0.27% 56.13 $
GSK 1.08% 50.82 $
RYCEF -1.22% 20.5 $
RELX 0.66% 36.54 $
NGG -0.1% 79.35 $
BCE 0.26% 23.46 $
Aytu BioPharma to Present at Upcoming September 2025 Conferences
Aytu BioPharma to Present at Upcoming September 2025 Conferences

Aytu BioPharma to Present at Upcoming September 2025 Conferences

BOULEVARD 24.09.2025

DENVER, CO / ACCESS Newswire / September 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced management will participate at the following investor conferences:

Text size:

MicroCap Rodeo Fall Conference

Date: Thursday, September 25, 2025
Location: New York City
Presentation Time: 2:00 p.m. Eastern time
Webcast: https://www.webcaster5.com/Webcast/Page/3142/53024

Lytham Partners Fall 2025 Investor Conference

Date: Tuesday, September 30, 2025
Location: Virtual
Presentation Time: 2:45 p.m. Eastern time
Webcast: https://app.webinar.net/K8vDlaelmAd

Management will be participating in one-on-one meetings throughout both events. To arrange a meeting with management, please contact Robert Blum of Lytham Partners at [email protected].

About Aytu BioPharma

Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), and a line of legacy products, including Karbinal® ER (carbinoxamine maleate), Poly-Vi-Flor® and Tri-Vi-Flor®. To learn more, please visit aytubio.com.

Contacts for Investors

Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]

Robert Blum
Lytham Partners
[email protected]

SOURCE: Aytu BioPharma, Inc.



View the original press release on ACCESS Newswire

A.Clark--AT

Featured

At least 8 die, more missing, as ferry capsizes off Northern Cyprus

At least 8 die, more missing, as ferry capsizes off Northern Cyprus
British woman dies after stabbing at German station

British woman dies after stabbing at German station
At least seven die in ferry capsize off Northern Cyprus; 23 missing

At least seven die in ferry capsize off Northern Cyprus; 23 missing
At least six die in ferry capsize off Northern Cyprus

At least six die in ferry capsize off Northern Cyprus